fli-1 Antibody

Definition and Molecular Role

Fli-1 antibodies detect the Fli-1 protein, a nuclear transcription factor implicated in cellular proliferation, differentiation, and tumorigenesis. Its dysregulation is linked to cancers like Ewing’s sarcoma, erythroleukemia, and vascular tumors. The antibody is used diagnostically to identify tumors driven by chromosomal translocations (e.g., EWS-FLI1 fusion in Ewing’s sarcoma) and to study autoimmune diseases such as systemic lupus erythematosus (SLE) .

Diagnostic Applications

Fli-1 antibodies are widely used in immunohistochemistry (IHC) to differentiate tumor types. Key findings include:

Table 1: Tumor Reactivity of Fli-1 Antibody

*Moderate specificity due to cross-reactivity with non-endothelial tumors (e.g., Merkel cell carcinoma, neuroendocrine tumors) .

Key Notes:

• Fli-1 is the first nuclear endothelial marker, reducing artifacts from cytoplasmic/membranous stains like CD31 or CD34 .

• It is ineffective for distinguishing benign vs. malignant vascular tumors .

Oncogenic Role

• Fli-1 overexpression drives leukemogenesis (e.g., Friend virus-induced erythroleukemia) and supports tumor survival via transcriptional activation of genes like SHIP-1 and gata-1 .

• In Ewing’s sarcoma, the EWS-FLI1 fusion protein is a diagnostic and therapeutic target .

Drug Development

• 30 compounds (e.g., glycosides like digoxin) inhibit Fli-1 DNA binding, reducing leukemic cell proliferation and inducing apoptosis .

• Camptothecin and etoposide suppress Fli-1 in graft-versus-host disease (GVHD) models while preserving graft-versus-leukemia effects .

Autoimmune Diseases

• Fli-1 overexpression in SLE and systemic sclerosis correlates with aberrant immune responses, making it a potential therapeutic target .

Table 2: Comparison of Fli-1 Antibody Clones

Key Notes:

• Monoclonal antibodies (e.g., G146-222) show higher specificity in vascular tumors compared to polyclonal variants .

• Western blot protocols recommend dilutions of 1:1,000–1:4,000 for optimal detection of the 51 kDa Fli-1 protein .

Research Validation and Challenges

• Enhanced validation methods (e.g., siRNA knockdown, GFP tagging) confirm antibody specificity .

• Cross-reactivity remains a challenge; Fli-1 stains non-endothelial cancers (e.g., 20% of lung adenocarcinomas) .